<DOC>
	<DOCNO>NCT02147431</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate effect semaglutide hypoglycaemic counter-regulation compare placebo subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Investigating Effect Semaglutide Hypoglycaemic Counterregulation Compared Placebo Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects diagnose type 2 diabetes stable treatment period 90 day prior screen metformin monotherapy . Stable define unchanged dose Male female , age between1864 year ( inclusive ) time sign informed consent Body Mass Index ( BMI ) 20.035.0 kg/m^2 ( inclusive ) HbA1c ( glycosylated haemoglobin ) 6.510.0 % ( inclusive ) Treatment glucose lower agent ( ) metformin period 90 day screen . An exception shortterm treatment ( less equal 7 day total ) insulin connection intercurrent illness Recurrent severe hypoglycaemia ( 1 severe hypoglycaemic event last 12 month ) hypoglycaemic unawareness judge investigator hospitalisation diabetic ketoacidosis previous 6 month Blood plasma donation within past month 500 mL within last 3 month prior first semaglutide dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>